Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1780 and Henagliflozin in chronic kidney disease
NCT06221059Phase 2Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-1780 in chronic kidney disease (CKD), sponsored by Shandong Suncadia Medicine Co., Ltd.. Started Mar 2024; status: completed.
02
Drugs
HRS-1780
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06221059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221059.